The Trump administration's announcement of tariffs up to 100% on certain imported patented pharmaceuticals has prompted an immediate and organised backlash from the pharmaceutical industry and patient advocacy groups, with formal responses expected Monday from major trade bodies including PhRMA and the Biotechnology Innovation Organization.

PhRMA, the primary lobbying arm of the branded drug industry, is expected to release a detailed economic impact statement Monday morning arguing that the tariffs — framed by the White House as a measure to reshore drug manufacturing — will instead increase out-of-pocket costs for American patients within 90 days, particularly for oncology and rare disease medicines that rely heavily on active pharmaceutical ingredients manufactured in India and China.

Several large pharmacy benefit managers, including CVS Caremark and Express Scripts, are anticipated to brief employer clients Monday on contingency scenarios, including accelerated formulary substitutions toward domestically produced generics where available. Analysts at Jefferies and Morgan Stanley have already flagged that specialty drug segments face the sharpest near-term cost exposure given limited domestic manufacturing alternatives.

Patient advocacy organisations, including the National Organization for Rare Disorders and the American Cancer Society Cancer Action Network, are preparing coordinated statements urging Congress to pass carve-out protections for medicines with no domestic equivalent. Both groups are expected to call on Senate HELP Committee Chair Bill Cassidy to hold emergency hearings on the tariff's health-system implications before the order takes effect.

The White House defended the measure Sunday, with trade adviser Peter Navarro characterising the tariffs as essential to national security and arguing that pharmaceutical supply chain dependence on foreign manufacturers poses unacceptable risk. The administration indicated implementation timelines and product-specific exemption criteria would be published in the Federal Register later this week, leaving industry stakeholders scrambling to assess exposure before formal rules are finalised.